Can we, should we, eradicate the meningococcus?

被引:11
|
作者
Maiden, Martin C. J. [1 ]
Frosch, Matthias [2 ]
机构
[1] Univ Oxford, Dept Zool, Oxford OX1 3PS, England
[2] Univ Wurzburg, Inst Fuer Hyg & Mikrobiol, D-97080 Wurzburg, Germany
基金
英国惠康基金;
关键词
Neisseria meningitidis; Vaccines; Epidemiology; Population biology; NEISSERIA-MENINGITIDIS; CARRIED MENINGOCOCCI; CONJUGATE VACCINE; SEROGROUP; DISEASE; IMMUNITY; IMMUNOGENICITY; DIVERSITY; EVOLUTION; VIRULENCE;
D O I
10.1016/j.vaccine.2011.12.068
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The eradication of infectious agents is an attractive means of disease control that, to date, has been achieved for only one human pathogen, the smallpox virus. The introduction of vaccines against Neisseria meningitidis into immunisation schedules, and particularly the conjugate polysaccharide vaccines which can interrupt transmission, raises the question of whether disease caused by this obligate human bacterium can be controlled, eliminated, or even eradicated. The limited number of meningococcal serogroups, lack of an animal reservoir, and importance of meningococcal disease are considerations in favour of eradication; however, the commensal nature of most infections, the high diversity of meningococcal populations, and the lack of comprehensive vaccines are all factors that suggest that this is not feasible. Indeed, any such attempt might be harmful by perturbing the human microbiome and its interaction with the immune system. On balance, the control and possible elimination of disease caused by particular disease-associated meningococcal genotypes is a more achievable and worthwhile goal. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:B52 / B56
页数:5
相关论文
共 50 条
  • [41] The State of Nutritional Epidemiology: Why We Are Still Unsure of What We Should Eat?
    Kamangar, Farin
    Karimi, Parisa
    ARCHIVES OF IRANIAN MEDICINE, 2013, 16 (08) : 483 - 486
  • [42] Chloroplast ion homeostasis - what do we know and where should we go?
    Kunz, Hans-Henning
    Armbruster, Ute
    Muehlbauer, Susanne
    de Vries, Jan
    Davis, Geoffry A.
    NEW PHYTOLOGIST, 2024, 243 (02) : 543 - 559
  • [43] Diversity, innovation and entrepreneurship: where are we and where should we go in future studies?
    Karlsson, Charlie
    Rickardsson, Jonna
    Wincent, Joakim
    SMALL BUSINESS ECONOMICS, 2021, 56 (02) : 759 - 772
  • [44] Deciphering the molecular basis of venous thromboembolism: where are we and where should we go?
    Morange, Pierre-Emmanuel
    Tregouet, David-Alexandre
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (04) : 495 - 506
  • [45] Genetic consequences of hunting: what do we know and what should we do?
    Harris, RB
    Wall, WA
    Allendorf, FW
    WILDLIFE SOCIETY BULLETIN, 2002, 30 (02): : 634 - 643
  • [46] Leadership and Counseling Psychology: What Should We Know? Where Could We Go?
    Fassinger, Ruth E.
    Shullman, Sandra L.
    COUNSELING PSYCHOLOGIST, 2017, 45 (07) : 927 - 964
  • [47] Pathogenesis of mastitis and mammary gland immunity: Where we are and where we should go
    Zecconi, A
    MASTITIS IN DAIRY PRODUCTION: CURRENT KNOWLEDGE AND FUTURE SOLUTIONS, 2005, : 31 - 40
  • [48] What is speciation and how should we study it?
    Wiens, JJ
    AMERICAN NATURALIST, 2004, 163 (06) : 914 - 923
  • [49] Diagnostic laparoscopy by physicians: We should do it
    Haydon, GH
    Hayes, PC
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 1997, 90 (04) : 297 - 304
  • [50] High Density Lipoprotein - Should we Raise it?
    Landmesser, Ulf
    CURRENT VASCULAR PHARMACOLOGY, 2012, 10 (06) : 718 - 719